Research & Innovation

Breakthroughs, discoveries, and new technologies from the Technion.

Health, Tech & Sustainability, Research & Innovation, Technion Israel

AI Tool Developed by Technion and University of Haifa Delivers Real-Time Data to Rescue Teams

/

Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.

Research & Innovation, Technion Israel

The Stability Paradox – How Do Organisms Change Shape Over the Course of Evolution?

/

Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.

Research & Innovation, Technion Israel

Innovative Satellite Network for Computed Tomography of Clouds to Improve Climate Predictions Will Be Initiated In Orbit

/

Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.

Research & Innovation, Technion Israel

At the Forefront of Global Microscopy: Technion Awarded Prestigious Research Grant

/

Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.

Awards & Recognition, Impact, Research & Innovation, Technion Israel

Recognizing the Technion’s Aerospace Stars

/

Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.

Research & Innovation, Technion Israel

Is Darkness Faster than Light?

/

Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.

Health, Tech & Sustainability, Research & Innovation, Technion Israel

Technion Researchers Develop AI Model to Predict Chemotherapy Benefit in Breast Cancer

/

Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.

Scroll to Top